Part:BBa_K4574004

Anti-IL-23A IGVL

Variable light chain locus of the human MOR-4649 monoclonal IgG1 antibody, which specifically targets human interleukin-23 subunit α (IL-23A). This component is integral to guselkumab, a therapeutic antibody used in the treatment of plaque psoriasis.

Source

The following basic part was developed for the therapeutic monoclonal antibody against human IL-23A by Benson et al.^[1].

The provided sequence was derived through back-translation from the resulting peptide. This back-translation took into account the codon usage bias for expression in mammalian cells (see "Usage and Biology" section). Additionally, the sequence was designed to comply with the BioBrick assembly standards.

Usage and Biology

This basic part has been used as a component of several antibody constructs in mammalian cell culture (HEK293T, Exi293, RAMOS).

Sequence and Features

Assembly Compatibility:

10
INCOMPATIBLE WITH RFC[10]
Illegal PstI site found at 238
12
INCOMPATIBLE WITH RFC[12]
Illegal PstI site found at 238
21
COMPATIBLE WITH RFC[21]
23
INCOMPATIBLE WITH RFC[23]
Illegal PstI site found at 238
25
INCOMPATIBLE WITH RFC[25]
Illegal PstI site found at 238
1000
COMPATIBLE WITH RFC[1000]

References

↑ Benson, J., Carton, J., Cunningham, M., Orlovsky, Y. I., Rauchenberger, R., & Sweet, R. (2007). Human anti-IL-23 antibodies, compositions, methods and uses (World Intellectual Property Organization Patent WO2007076524A2). https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007076524

[1] Benson, J., Carton, J., Cunningham, M., Orlovsky, Y. I., Rauchenberger, R., & Sweet, R. (2007). Human anti-IL-23 antibodies, compositions, methods and uses (World Intellectual Property Organization Patent WO2007076524A2). https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007076524

[1]